Informations générales (source: ClinicalTrials.gov)
Involvement of the Mediodorsal Nucleus of the Thalamus in Higher Order Cognitive Processes : a Study in Patients With a Thalamic Infarct
Interventional
N/A
University Hospital, Toulouse (Voir sur ClinicalTrials)
mai 2019
avril 2023
29 août 2025
The aim is to expand evidence about the importance of the mediodorsal nucleus of the
thalamus as a key node in human higher-order cognitive functions such as learning,
decision-making, and adaptive behavior. Thus, the project proposes to assess global
cognition along with higher-order cognition integrity via sensitive behavior tasks in
patients with well localized lesions (mediodorsal thalamic infarcts) compared with
healthy participants.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hopital Purpan - CHU de Toulouse - 31059 - Toulouse - France | Jérémie PARIENTE, MD, PHD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion criteria for patients:
- French as their mother tongue
- Absence of cognitive deterioration before the stroke.
- Visual, auditory (equipment authorized) and oral or written skills sufficient for
the proper assessment using neuropsychological tests.
- First infarct affecting the thalamus.
- At least seven years' schooling from primary school
- Signed informed consent
- Chronic lesion (> 3 months)
Inclusion criteria for controls:
- French as their mother tongue
- Absence of cognitive complain
- Visual, auditory (equipment authorized) and oral or written skills sufficient for
the proper assessment using neuropsychological tests.
- At least seven years of school from primary school
- Signed informed consent
Exclusion criteria for patients:
- Neurological deficit or significant residual disability at inclusion.
- Aphasia, agnosia, apraxia or severe neglect, as demonstrated by clinical examination
and neuropsychological tests.
- Subjects with a contraindication to MRI.
- General, neurological or psychiatric progressive disease.
Exclusion criteria for controls:
- Subjects with a contraindication to MRI.
- General, neurological or psychiatric progressive disease.
- French as their mother tongue
- Absence of cognitive deterioration before the stroke.
- Visual, auditory (equipment authorized) and oral or written skills sufficient for
the proper assessment using neuropsychological tests.
- First infarct affecting the thalamus.
- At least seven years' schooling from primary school
- Signed informed consent
- Chronic lesion (> 3 months)
Inclusion criteria for controls:
- French as their mother tongue
- Absence of cognitive complain
- Visual, auditory (equipment authorized) and oral or written skills sufficient for
the proper assessment using neuropsychological tests.
- At least seven years of school from primary school
- Signed informed consent
Exclusion criteria for patients:
- Neurological deficit or significant residual disability at inclusion.
- Aphasia, agnosia, apraxia or severe neglect, as demonstrated by clinical examination
and neuropsychological tests.
- Subjects with a contraindication to MRI.
- General, neurological or psychiatric progressive disease.
Exclusion criteria for controls:
- Subjects with a contraindication to MRI.
- General, neurological or psychiatric progressive disease.